Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

BioCorRx (BICX) Equity Average (2016 - 2025)

BioCorRx's Equity Average history spans 15 years, with the latest figure at -$235705.0 for Q3 2025.

  • For Q3 2025, Equity Average rose 97.96% year-over-year to -$235705.0; the TTM value through Sep 2025 reached -$235705.0, up 97.96%, while the annual FY2024 figure was -$1.2 million, 237.24% down from the prior year.
  • Equity Average for Q3 2025 was -$235705.0 at BioCorRx, down from $12.4 million in the prior quarter.
  • Across five years, Equity Average topped out at $12.4 million in Q2 2025 and bottomed at -$12.2 million in Q4 2024.
  • The 5-year median for Equity Average is -$6.9 million (2022), against an average of -$5.1 million.
  • The largest annual shift saw Equity Average tumbled 3619.39% in 2024 before it soared 212.71% in 2025.
  • A 5-year view of Equity Average shows it stood at -$6.4 million in 2021, then dropped by 20.66% to -$7.7 million in 2022, then soared by 104.49% to $346060.5 in 2023, then crashed by 3619.39% to -$12.2 million in 2024, then surged by 98.06% to -$235705.0 in 2025.
  • Per Business Quant, the three most recent readings for BICX's Equity Average are -$235705.0 (Q3 2025), $12.4 million (Q2 2025), and -$276828.5 (Q1 2025).